InvestSMART

Acumentis Group Limited (ASX: ACU) - Announcements

- Current share price for ACU : $0.095

ASX company news and announcements for Acumentis Group Limited (ACU) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Acumentis Group Limited (ACU) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Acumentis Group Limited (ACU), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Acumentis Group Limited (ACU)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$21 First drug master file submitted to US FDA 7 Apr 2005 8:57AM $0.159 $0.095 fallen by 40.14%
$21 $5.7m fully underwritten non-renouceable rights issue 4 Apr 2005 3:25PM $0.145 $0.095 fallen by 34.53%
$21 Dismisses Merger Speculation 18 Mar 2005 2:58PM $0.181 $0.095 fallen by 47.63%
$21 Doubling of Mean Survival Time 9 Feb 2005 10:08AM $0.304 $0.095 fallen by 68.73%
$21 US Biotech invests in AustCancer & 1 for 10 Rights Issue 6 Oct 2004 5:04PM $0.330 $0.095 fallen by 71.19%
$21 Fund Ongoing Project Dev/Working Capital Purposes 13 Sep 2004 5:06PM $0.398 $0.095 fallen by 76.10%
$21 AustCancer Licenses Phase I/II Pancreatic Cancer Drug 10 Sep 2004 8:35AM $0.411 $0.095 fallen by 76.89%
$21 A$3.8 M Placement to Global Institutions 1 Sep 2004 2:11PM $0.384 $0.095 fallen by 75.26%
$21 Trading Halt 1 Sep 2004 9:58AM $0.384 $0.095 fallen by 75.26%
$21 US ADR Program Established 28 Jun 2004 8:58AM $0.438 $0.095 fallen by 78.32%
$21 To acquire US Vaccine Developer 21 May 2004 8:44AM $0.425 $0.095 fallen by 77.63%
$21 Phase II Cancer Vaccine Trial Underway 30 Apr 2004 10:53AM $0.370 $0.095 fallen by 74.35%
$21 Phase II Cancer Vaccine Trial Underway 30 Apr 2004 10:53AM $0.370 $0.095 fallen by 74.35%
$21 Commitments Test Entity - Third Quarter Report 28 Apr 2004 8:44AM $0.380 $0.095 fallen by 74.97%
$21 Phase II Pentrix trial to commence 13 Apr 2004 11:28AM $0.325 $0.095 fallen by 70.80%
$21 Phase II Pentrix trial to commence 13 Apr 2004 11:28AM $0.325 $0.095 fallen by 70.80%
$21 Australian Cancer Tech.Announces Successful Capital Raising 16 Mar 2004 5:41PM $0.294 $0.095 fallen by 67.64%
$21 Half Yearly Report & Accounts 27 Feb 2004 1:52PM $0.334 $0.095 fallen by 71.58%
$21 Response to ASX Appendix 4C Query 11 Feb 2004 7:05PM $0.298 $0.095 fallen by 68.14%
$21 Phase II Anti-Cancer Vaccine Trial Approved 19 Dec 2003 11:32AM $0.190 $0.095 fallen by 49.92%
$21 Commitments Test Entity - First Quarter Report 27 Oct 2003 3:03PM $0.172 $0.095 fallen by 44.67%
$21 Preliminary Final Report 12 Sep 2003 2:04PM $0.203 $0.095 fallen by 53.27%
$21 Important Cancer Drug Discovery from AustCancer JV 1 Sep 2003 11:40AM $0.226 $0.095 fallen by 57.95%
$21 New CEO Appointment & Capital Raising 14 Aug 2003 12:51PM $0.154 $0.095 fallen by 38.15%
$21 Acquisition of US Cancer Care Business 14 Aug 2003 12:50PM $0.154 $0.095 fallen by 38.15%

576 - 600 of 601 results

Page 24 of 25

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.